If the US Food and Drug Administration gets its way, pandemic response legislation that expires this year would be reauthorized with a set of provisions that help the agency see more deeply into pharmaceutical supply chains and help make sure they deliver enough quality products to meet demand.
As part of its fiscal year 2024 budget submission, the agency outlined eight drug-related legislative proposals for the next...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?